Research projects and third-party funding

♦ FWF Stand-Alone Project (“Designer Receptor Gene Therapy constructed for Parkinson’s – DR-GeTuP”), from the Austrian science fund. (405 720.00 €)

♦ Therapeutic Acceleration Support (TAS) (“Enhanced KCC2 gene therapy for refractory epilepsy”), from the Wellcome Trust together with Dimitri M. Kullmann. (77 384.66 £)

♦ BRC Therapeutic Innovation Call (“Inhibitory designer receptor exclusively activated by designer drugs (DREADD) preparation for translational research”), from the NIHR BRC UCLH National Institute for Health Research University College London Hospitals Biomedical Research Centre together with Dimitri M. Kullmann (79 572 £)

♦ Innovator Award (“Glutamate-gated chloride channel treatment of epilepsy“; dedicated to close the gap between basic research and clinical translation), from the Wellcome Trust together with Prof. Dimitri M. Kullmann. (456 266 £)

♦ Marie Sklodowska Curie Individual Fellowship (AutoStopS – Autoinhibition to Stop Seizures), from the European Commission (H2020-MSCA-IF-2015). (137 591 €)

Institut für Pharmakologie

Research projects and third-party funding

♦ FWF Stand-Alone Project (“Designer Receptor Gene Therapy constructed for Parkinson’s – DR-GeTuP”), from the Austrian science fund. (405 720.00 €)

♦ Therapeutic Acceleration Support (TAS) (“Enhanced KCC2 gene therapy for refractory epilepsy”), from the Wellcome Trust together with Dimitri M. Kullmann. (77 384.66 £)

♦ BRC Therapeutic Innovation Call (“Inhibitory designer receptor exclusively activated by designer drugs (DREADD) preparation for translational research”), from the NIHR BRC UCLH National Institute for Health Research University College London Hospitals Biomedical Research Centre together with Dimitri M. Kullmann (79 572 £)

♦ Innovator Award (“Glutamate-gated chloride channel treatment of epilepsy“; dedicated to close the gap between basic research and clinical translation), from the Wellcome Trust together with Prof. Dimitri M. Kullmann. (456 266 £)

♦ Marie Sklodowska Curie Individual Fellowship (AutoStopS – Autoinhibition to Stop Seizures), from the European Commission (H2020-MSCA-IF-2015). (137 591 €)

Research projects and third-party funding

♦ FWF Stand-Alone Project (“Designer Receptor Gene Therapy constructed for Parkinson’s – DR-GeTuP”), from the Austrian science fund. (405 720.00 €)

♦ Therapeutic Acceleration Support (TAS) (“Enhanced KCC2 gene therapy for refractory epilepsy”), from the Wellcome Trust together with Dimitri M. Kullmann. (77 384.66 £)

♦ BRC Therapeutic Innovation Call (“Inhibitory designer receptor exclusively activated by designer drugs (DREADD) preparation for translational research”), from the NIHR BRC UCLH National Institute for Health Research University College London Hospitals Biomedical Research Centre together with Dimitri M. Kullmann (79 572 £)

♦ Innovator Award (“Glutamate-gated chloride channel treatment of epilepsy“; dedicated to close the gap between basic research and clinical translation), from the Wellcome Trust together with Prof. Dimitri M. Kullmann. (456 266 £)

♦ Marie Sklodowska Curie Individual Fellowship (AutoStopS – Autoinhibition to Stop Seizures), from the European Commission (H2020-MSCA-IF-2015). (137 591 €)